Epidemiological effectiveness of domestic influenza vaccines in cases with vaccination against a new coronavirus infection in 2022–2023

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

The study presents the results of an epidemiological prospective field cohort study on a comparative assessment of the epidemiological effectiveness of domestic inactivated influenza vaccines and vaccines against new coronavirus infection during immunization of adults aged >18 years. Statistically significant differences were found in the incidence of influenza, acute upper respiratory infections, and new coronavirus infection between the vaccinated and unvaccinated groups. The etiologies of cases of acute upper respiratory infections registered in the study participants during the epidemic season of influenza in 2022–2023 were verified. The clinical symptoms of influenza in the vaccinated group were significantly less severe than those in the unvaccinated group. No significant differences were found in the clinical picture of acute upper respiratory infections between the compared groups. Influenza immunoprophylaxis is an urgent problem, which consists of the ability of viruses to change their antigenic structure and avoid immunity, remaining in constant circulation. Thus, the antigenic composition of influenza vaccines must be systematically updated to ensure the formation of effective population immunity. More studies on the etiological spectrum of respiratory pathogens and assessment of the epidemiological effectiveness of vaccination against vaccine-controlled infections in the analyzed groups are needed. Therefore, to assess immunological protection, including the assessment of the epidemiological effectiveness of seasonal vaccines used against influenza and new coronavirus infection, the priority age group includes individuals aged 18–25 years (especially those belonging to organized collectives) and adults with an unfavorable premorbid background. The use of domestic vaccines against influenza and the new coronavirus infection for specific immunoprophylaxis is generally recognized as the most effective sanitary and anti-epidemic (preventive) measure in the morbidity management of several infectious diseases.

About the authors

Dmitry A. Lioznov

The Smorodintsev Research Institute of Influenza; Academician I.P. Pavlov First St. Petersburg State Medical University

Email: dmitry.lioznov@influenza.spb.ru
ORCID iD: 0000-0003-3643-7354
SPIN-code: 3321-6532
Scopus Author ID: 8634494900

MD, Dr. Sci. (Med.), professor

Russian Federation, Saint Petersburg; Saint Petersburg

Aleksandr A. Kuzin

Kirov Military Medical Academy

Email: paster-spb@mail.ru
ORCID iD: 0000-0001-9154-7017
SPIN-code: 6220-1218

MD, Dr. Sci. (Med.), professor

Russian Federation, Saint Petersburg

Andrey Е. Zobov

Kirov Military Medical Academy

Author for correspondence.
Email: dr.andrey98@yandex.ru
ORCID iD: 0000-0001-7791-8993
SPIN-code: 4281-2680

MD, Cand. Sci. (Med.)

Russian Federation, Saint Petersburg

Ruslan I. Glushakov

Kirov Military Medical Academy

Email: glushakoffruslan@yandex.ru
ORCID iD: 0000-0002-0161-5977
SPIN-code: 6860-8990

MD, Dr. Sci. (Med.)

Russian Federation, Saint Petersburg

Mariana K. Erofeeva

The Smorodintsev Research Institute of Influenza

Email: mariana.erofeeva@influenza.spb.ru
ORCID iD: 0000-0003-1860-3857
SPIN-code: 8908-9867

MD, Dr. Sci. (Med.)

Russian Federation, Saint Petersburg

Marina А. Stukova

The Smorodintsev Research Institute of Influenza

Email: marina.stukova@influenza.spb.ru
ORCID iD: 0000-0002-2127-3820
SPIN-code: 5748-9310

MD, Cand. Sci. (Med.)

Russian Federation, Saint Petersburg

Zhanna V. Buzitskaya

The Smorodintsev Research Institute of Influenza

Email: janna.buzitskaya@influenza.spb.ru
ORCID iD: 0000-0002-8394-102X
SPIN-code: 9055-8328

candidate of biological sciences

Russian Federation, Saint Petersburg

Oleg Y. Golubtsov

Kirov Military Medical Academy

Email: doctorwox@yandex.ru
ORCID iD: 0000-0001-6933-9457
SPIN-code: 9954-1960

head of department

Russian Federation, Saint Petersburg

References

  1. Global Influenza Program. Geneva: World Health Organization (WHO). 2010. P. 2–6.
  2. Belov AB, Ogarkov PI. Current issues of epidemiology and immunization respiratory infection in the population and the military. Epidemiology and Vaccinal Prevention. 2012;1(62):4–11. (In Russ.).
  3. Akimkin VG, Salmina TA, Shevtsov VA, Kalabukhova LYu. Assessment of the sanitary and epidemiological situation on the incidence of influenza A(H1N1)sw-09 in organized collectives of the Moscow region. Infection Diseases. 2010;8(1):12. (In Russ.)
  4. Belov AB, Ogarkov PI. Epidemiology and prophylaxis of influenza and other acute respiratory infections occurred in the 32 military collectives. Military Medical Journal. 2005;326(3):31–38. (In Russ.)
  5. Belov AB, Ogarkov PI. Epidemiological aspects of the influenza «pandemia» during 2009-2010 years. Voenno-meditsinskii Zhurnal. 2010;(11):37–41. (In Russ.) doi: 10.17816/RMMJ75172
  6. Grohskopf LA, Alyanak E, Broder KR, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices – United States, 2020–21 Influenza Season. MMWR Recomm Rep. 2020;69(8):1–24. doi: 10.15585/mmwr.rr6908a1
  7. Dinleyici EC, Borrow R, Safadi MAP, et al. Vaccines and routine immunization strategies during the COVID-19 pandemic. Hum Vaccin Immunother. 2021;17(2):400–407. doi: 10.1080/21645515.2020.1804776
  8. Gostin LO, Salmon DA. The Dual Epidemics of COVID-19 and Influenza: Vaccine Acceptance, Coverage, and Mandates. JAMA. 2020;324(4):335–336. doi: 10.1001/jama.2020.10802
  9. Singer VD. COVID-19 and the next influenza season. Sci Adv. 2020;6(31):eabd0086. doi: 10.1126/sciadv.abd0086
  10. Doyle JD, Chung JR, Kim SS, et al. Interim Estimates of 2018–19 Seasonal Influenza Vaccine Effectiveness – United States, February 2019. MMWR Morb Mortal Wkly Rep. 2019;68(6):135–139. doi: 10.15585/mmwr.mm6806a2
  11. Paget J, Caini S, Cowling B, et al. The impact of influenza vaccination on the COVID-19 pandemic? Evidence and lessons for public health policies. Vaccine. 2020;38(42):6485–6486. doi: 10.1016/j.vaccine.2020.08.024
  12. Maltezo HC, Theodoridou K., Poland G. Influenza immunization and COVID-19. Vaccine. 2020;38(39):6078–6079. doi: 10.1016/j.vaccine.2020.07.058
  13. Grech V, Borg M. Influenza vaccination in the COVID-19 era. Early Hum Dev. 2020;148:105116. doi: 10.1016/j.earlhumdev.2020.105116
  14. Kuznetsov OK, Stepanova LA, Churikova AA, еt al. Population immunity to the seasonal influenza is the main factor limiting the global epidemic 2009 – 2010. A(H1N1). Epidemiology and Vaccinal Prevention. 2010;(4):9–17. (In Russ.).
  15. Kryukov EV, Trishkin D V, Ivanov AM, et al. Comparative cohort epidemiological study of collective immunity against new coronavirus infection among different groups of military personnel. Annals of the Russian Academy of Medical Sciences. 2021;76(6):661–668. (In Russ.). doi: 10.15690/vramn1583
  16. Kasyanenko KV, Kozlov KV, Maltsev OV, et al. Evaluation of the effectiveness of riamilovir in the complex therapy of COVID-19 patients. Therapeutic Archive. 2021;93(3):290–294. (In Russ.). doi: 10.26442/00403660.2021.03.200719
  17. Kasyanenko KV, Maltsev OV, Kozlov KV, et al. Clinical Efficiency and Safety of Riamilovir for Treating Patients with SARS-CoV-2 Infection. Antibiotics and Chemotherapy. 2020;65(11–12):16–21. (In Russ.). doi: 10.37489/0235-2990-2020-65-11-12-16-21

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. Frequency of detection of viral acute respiratory infections pathogens among study participants based on the laboratory examination results of nasopharyngeal smears

Download (372KB)
3. Fig. 2. Verification of pathogens of viral acute respiratory infections in nasopharyngeal smears by polymerase chain reaction in cases of mixed infections in the vaccinated group

Download (220KB)

Copyright (c) 2023 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies